Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call
Rhea-AI Summary
Spectral AI (Nasdaq: MDAI) will release its 2026 second quarter financial results for the period ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq market. A conference call to discuss the results is scheduled for 5:00 p.m. Eastern Time the same day, with U.S. and international dial-in numbers and a simultaneous webcast available via the Events section of the company’s investor relations website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 08 | commercial appointment | Positive | -0.6% | Named Darcy Bajko chief commercial officer to lead global DeepView commercialization. |
| Jun 25 | conference presentation | Positive | +0.6% | Presented DeepView research and received a first-prize oral presentation award. |
| Jun 12 | awareness partnership | Positive | -2.1% | Partnered with the wound management foundation for Wound Healing Awareness Month. |
| Jun 11 | conference participation | Positive | +1.6% | Announced conference participation and projected first commercial sales by year-end 2026. |
| Jun 01 | annual meeting results | Neutral | -1.9% | Reported approval of annual meeting proposals, including share reservation authorization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news produced mixed reactions, with three of five events showing negative 24-hour price changes despite generally positive or neutral announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.
Investors interested in participating in the live call can dial into the conference call as follows:
- 833-890-6620 – U.S.
- 412-564-3789 – International
In addition, a simultaneous webcast of the financial results call may be accessed online from the Events section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
| Investors: The Equity Group | |
| Devin Sullivan Managing Director Devin.Sullivan@theequitygroup.com | Conor Rodriguez Associate Conor.Rodriguez@theequitygroup.com |
